• Login
    View Item 
    •   Home
    • Hospital Research
    • Munster
    • Mercy University Hospital
    • View Item
    •   Home
    • Hospital Research
    • Munster
    • Mercy University Hospital
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Map of Submissions

    Home Page
    UlsterN
    4673
    UlsterS
    4673
    Connacht
    1594
    Munster
    48
    Leinster
    425

    Browse

    All of Lenus, The Irish Health RepositoryCommunitiesTitleAuthorsDate publishedSubjectsThis CollectionTitleAuthorsDate publishedSubjects

    My Account

    LoginRegister

    About

    About LenusDirectory of Open Access JournalsOpen Access Publishing GuideNational Health Library & Knowledge ServiceGuide to Publishers' PoliciesFAQsTerms and ConditionsVision StatementRIAN Pathways to Irish ResearchHSE position statement on Open AccessNational Open Research Forum (NORF)Zenodo (European Open Research repository)

    Statistics

    Display statistics

    Novel agents in the management of lung cancer.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Kennedy, B
    Gargoum, F
    Bystricky, B
    Curran, D R
    O'Connor, T M
    Affiliation
    Department of Respiratory Medicine, Mercy University Hospital, Cork, Ireland.
    Issue Date
    2012-01-31T16:39:07Z
    MeSH
    Antineoplastic Agents/chemistry/pharmacology/*therapeutic use
    Epidermal Growth Factor/antagonists & inhibitors/metabolism
    Humans
    Lung Neoplasms/*drug therapy/metabolism
    Molecular Structure
    Signal Transduction/drug effects
    Vascular Endothelial Growth Factor A/antagonists & inhibitors/metabolism
    
    Metadata
    Show full item record
    Citation
    Curr Med Chem. 2010;17(35):4291-325.
    Journal
    Current medicinal chemistry
    URI
    http://hdl.handle.net/10147/206262
    PubMed ID
    20939812
    Abstract
    Lung cancer is the leading cause of cancer death worldwide. Survival remains poor as approximately 80% of cases present with advanced stage disease. However, new treatments are emerging which offer hope to patients with advanced disease. Insights into cell biology have identified numerous intracellular and extracellular peptides that are pivotal in cancer cell signalling. Disrupting the function of these peptides inhibits intracellular signal transduction and diminishes uncontrolled proliferation, resistance to apoptosis and tumour angiogenesis. The most widely studied signalling pathway is the Epidermal Growth Factor (EGF) pathway. EGF signalling can be disrupted at numerous points. Blockade of the cell surface receptor is achieved by the monoclonal antibody cetuximab; intracellular tyrosine kinase activity is inhibited by erlotinib. Vascular Endothelial Growth Factor (VEGF) regulates another pathway important for tumour growth. Inhibition of VEGF impairs angiogenesis and disrupts metastatic spread. Bevacizumab is a monoclonal antibody that binds to VEGF and blocks interaction with its cell surface receptor. Clinical trials have demonstrated that disruption of these signalling pathways can improve survival in advanced lung cancer. New compounds including folate antimetabolites such as pemetrexed, proteasome inhibitors such as bortezomib, modified glutathione analogues such as TLK286, and other agents such as epothilones and other small molecules are currently being evaluated in patients with lung cancer. As more and more signalling peptides are targeted for manipulation, it is hoped that a new era is dawning in the treatment of advanced stage lung cancer. This review will focus on emerging new therapies in the management of lung cancer.
    Language
    eng
    ISSN
    1875-533X (Electronic)
    0929-8673 (Linking)
    Collections
    Mercy University Hospital

    entitlement

    Related articles

    • Targeted therapy in advanced non-small-cell lung cancer.
    • Authors: Gettinger S
    • Issue date: 2008 Jun
    • Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor.
    • Authors: Kelly K, Huang C
    • Issue date: 2008 Jun
    • The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.
    • Authors: Langer C, Soria JC
    • Issue date: 2010 Mar 1
    • Targeted therapies for non-small cell lung cancer: an evolving landscape.
    • Authors: Pal SK, Figlin RA, Reckamp K
    • Issue date: 2010 Jul
    • Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.
    • Authors: Pakkala S, Ramalingam SS
    • Issue date: 2009 Mar
    National Health Library & Knowledge Service | Health Service Executive | Dr Steevens' Hospital | Dublin 8 | Ireland
    lenus@hse.ie | Tel +353 (1) 6352558
    DSpace software copyright © 2002-2017  DuraSpace
    Contact Us | Disclaimer
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.